FDA staff leave Galleri’s early-detection claim unresolved before panel review

Sep 21, 6:12 PM UTC

No outstanding staff questions, but intended-use evidence remains under review

FDA briefing documents said staff had no outstanding questions for advisers about Galleri’s analytical performance, study design or primary safety analyses, but that does not constitute an affirmative finding that the test is accurate, safe or effective. Staff asked whether the evidence supports describing Galleri as an “early detection” test—a central issue because its intended use is screening adults 50 or older for cancer signals before diagnostic follow-up. GRAIL previously said routine screening in its pivotal three-year UK trial did not significantly increase early detection or reduce late-stage diagnoses. The September 23 advisory panel will discuss and vote on the premarket-approval application; its recommendation is nonbinding and is not FDA approval. This briefing covers 2026-09-20T06:08:37.502Z through 2026-09-21T18:08:37.502Z. The timestamp is Reuters publication metadata, not the documents’ release time.

FDA advisory committee meeting announcement for GRAIL’s Galleri test · Grail rallies as FDA staff flags no major concerns for multi-cancer test